Negociado por el gobierno argentino bajo los principios de solidaridad ante la emergencia sanitaria mundial y distribución con equidad de la vacuna en LA.
Lo anunció el Presidente Alberto Fernández. Convenio entre University of Oxford and AstraZeneca para producir la vacuna COVID-19, desarrollada por el consorcio, en Argentina y México destinada a AL. Financia la producción Carlos Slim (fundación) de México y, en el país, la fabricación del principio vacunal estará en cabeza de la firma biotech mAbxience (responsable de la transferencia de tecnología productiva y estructura comercial).
Recordemos que la vacuna consiste en un chimpanzee adenovirus-vectored vaccine (ChAdOx1 nCoV-19) expressing the SARS-CoV-2 spike protein.
UK Research and Innovation, Coalition for Epidemic Preparedness Innovations, National Institute for Health Research (NIHR), NIHR Oxford Biomedical Research Centre, Thames Valley and South Midland’s NIHR Clinical Research Network, and the German Center for Infection Research (DZIF), Partner site Gießen-Marburg-Langen.
About the COVID-19 Vaccine (fuente: https://covid19vaccinetrial.co.uk/about)
A chimpanzee adenovirus vaccine vector (ChAdOx1), developed at Oxford’s Jenner Institute, was chosen as the most suitable vaccine technology for a SARS-CoV-2 vaccine as it can generate a strong immune response from one dose and it is not a replicating virus, so it cannot cause an ongoing infection in the vaccinated individual. This also makes it safer to give to children, the elderly and anyone with a pre-existing condition such as diabetes. Chimpanzee adenoviral vectors are a very well-studied vaccine type, having been used safely in thousands of subjects, from 1 week to 90 years of age, in vaccines targeting over 10 different diseases.
Coronaviruses have club-shaped spikes on their outer coats. Immune responses from other coronavirus studies suggest that these are a good target for a vaccine. The Oxford vaccine contains the genetic sequence of this surface spike protein inside the ChAdOx1 construct. After vaccination, the surface spike protein of the coronavirus is produced, which primes the immune system to attack the coronavirus if it later infects the body. Prof. Gilbert and team have previously developed a vaccine for another human coronavirus disease, which is Middle East Respiratory Syndrome (MERS), and this has shown promise in early clinical trials.
Para más información:
* Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial (Lancet, Published:July 20, 2020).
fabiofcantafio 